Save for later
A bipartisan New York duo is proposing a change in House rules that would prohibit members from serving on serving on the boards of publicly held companies, the latest fallout from the indictment of Rep. Chris Collins, R-N.Y., for insider trading.
Collins served on the board of Innate Immunotherapeutics, an Australian biotechnology company, and allegedly shared inside knowledge about Innate’s drug trial results with his son, who then made timely stock trades.
